Skip to main content
. 2020 Oct 19;26(6):312–320. doi: 10.4103/sjg.SJG_30_20

Figure 1.

Figure 1

(a) Percentage of patients with EBV-DNA positivity in blood in different groups aP, 0.039, UC versus CD; bP,0.121, refractory UC versus nonrefractory UC; cP, 0.458, refractory CD versus nonrefractory CD Percentage of patients with EBER-1 positive in mucosal in different groups. aP, 0.012, UC versus CD;bP, 0.191, refractory UC versus nonrefractory UC; cP, 0.019, refractory CD versus nonrefractory CD